000157469 001__ 157469
000157469 005__ 20240303004307.0
000157469 0247_ $$2doi$$a10.1186/s13148-020-00904-7
000157469 0247_ $$2pmid$$apmid:32778176
000157469 0247_ $$2ISSN$$a1868-7075
000157469 0247_ $$2ISSN$$a1868-7083
000157469 0247_ $$2altmetric$$aaltmetric:148841170
000157469 037__ $$aDKFZ-2020-01648
000157469 041__ $$aeng
000157469 082__ $$a610
000157469 1001_ $$0P:(DE-He78)43ea0369702f56d45fa4a32df9f49aca$$aRaut, Janhavi$$b0$$eFirst author$$udkfz
000157469 245__ $$aFecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review.
000157469 260__ $$a[S.l.]$$bBioMed Central$$c2020
000157469 3367_ $$2DRIVER$$aarticle
000157469 3367_ $$2DataCite$$aOutput Types/Journal article
000157469 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600154372_29002$$xReview Article
000157469 3367_ $$2BibTeX$$aARTICLE
000157469 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157469 3367_ $$00$$2EndNote$$aJournal Article
000157469 500__ $$a#EA:C120#LA:C070
000157469 520__ $$aDNA methylation biomarkers in stool may have applications in early colorectal cancer (CRC) detection; however, their association with stages of CRC carcinogenesis or their performance in detecting various stages is unclear. We aimed to systematically review the evidence for DNA methylation markers in stool for risk stratification or detection of specific CRC stages, as well as precursors of CRC.We conducted a systematic search in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched PubMed and ISI Web of Knowledge to identify relevant studies published until 14th January 2020. Two reviewers independently extracted data on study population characteristics, candidate genes, methylation measurement methods, odds ratios (ORs), overall and stage-specific sensitivities, specificities, areas under the receiver operating characteristics curve, and p-values for statistical significance for OR and for association of methylation levels with stage.Twenty-seven studies that reported stage-specific associations or performances of fecal DNA methylation markers for detecting colorectal neoplasms were identified. All studies used methylation-specific polymerase chain reaction for assessing methylation levels in the promoter or exon 1 regions of targeted genes. However, most studies were underpowered and limited by their case-control design. Furthermore, the stage-specific associations or sensitivities were validated for two markers (hypermethylation of GATA4 and VIM) only.Methylation markers in stool may be useful for detection of CRC precursors or CRC staging, but promising candidate markers need to be validated in longitudinal studies on large screening populations, performing epigenome-wide analyses. Identification of stage-specific DNA methylation biomarkers in stool could boost current strategies towards early detection and enable different approaches to precision medicine for CRC.
000157469 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000157469 588__ $$aDataset connected to CrossRef, PubMed,
000157469 7001_ $$0P:(DE-He78)e2927c4f5c050e0ad98ebb65eebe0d56$$aGuan, Zhong$$b1
000157469 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b2$$udkfz
000157469 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000157469 773__ $$0PERI:(DE-600)2553921-8$$a10.1186/s13148-020-00904-7$$gVol. 12, no. 1, p. 122$$n1$$p122$$tClinical epigenetics$$v12$$x1868-7083$$y2020
000157469 909CO $$ooai:inrepo02.dkfz.de:157469$$pVDB
000157469 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)43ea0369702f56d45fa4a32df9f49aca$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157469 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e2927c4f5c050e0ad98ebb65eebe0d56$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000157469 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000157469 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000157469 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157469 9141_ $$y2020
000157469 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN EPIGENETICS : 2018$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2019-12-20
000157469 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN EPIGENETICS : 2018$$d2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2019-12-20
000157469 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2019-12-20
000157469 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000157469 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000157469 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000157469 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000157469 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000157469 980__ $$ajournal
000157469 980__ $$aVDB
000157469 980__ $$aI:(DE-He78)C120-20160331
000157469 980__ $$aI:(DE-He78)C070-20160331
000157469 980__ $$aI:(DE-He78)HD01-20160331
000157469 980__ $$aUNRESTRICTED